This study assessed the functional capacity of sub-acute SCT recipients using validated physical performance tests, including 6-min walk distance, repeated sit-to-stand time and 50-ft walk time, and compared these outcomes with those reported for a heterogeneous oncology population. The medical records of 80 consecutive sub-acute SCT recipients not receiving corticosteroids were retrospectively reviewed for demographic, medical and anthropometric information, and outcomes for these physical performance tests administered at the time of initial physiotherapy evaluation. Measures of central tendency, 95% confidence intervals, unpaired t-tests and correlation coefficients were calculated using a SPSS statistical package. SCT recipients completed the 50-ft walk in 10.66 ± 4.43 s, repeated sit-to-stand trial in 4.16 ± 1.82 s and walked 400.2 m in 6 min. For the timed tests, SCT recipients were approximately twice as fast as a heterogeneous group of oncology patients and walked approximately 50% further in 6 min. No overlap in the 95% confidence intervals for the two groups was observed for any of the tests. These results (1) suggest that reference values describing the functional capacity of a heterogeneous oncology population underestimate the functional capacity of SCT recipients and (2) provide clinically useful reference values for assessing functional capacity of sub-acute SCT recipients referred for physiotherapy.
Introduction
The use of SCT to treat hematological malignancies has increased in recent years. However, available data suggest that pre-transplantation chemotherapy and the transplant process leave many of these patients with substantial physical and functional deficits. [1] [2] [3] As such, physical rehabilitation of these patients becomes an important post-transplant therapeutic intervention which is often directed by rehabilitation specialists, including occupational and physical therapists. 4, 5 Central to the success of this rehabilitation process is an understanding of the initial physical and functional status of the patient and an ability to monitor changes in patient status over the course of rehabilitation treatment. A battery of physical performance tests has recently been described that are valid and reliable in the oncology population, well tolerated by patients, completed quickly and easily used by clinicians. 6 It is important to note that results from these physical performance tests are moderately correlated with patient self report of functional capacity and hence, their outcomes provide insight into the functional and physical capacity of these patients. 6 Several investigators have used these physical performance tests to describe treatment and temporal changes in the physical and functional capacity of patients with specific oncology diagnoses, including lung and breast cancer patients as well as oncology patients receiving palliative care. [7] [8] [9] [10] However, the outcomes reported in these studies vary substantially from the normative values reported by Simmonds. 6 Although these studies demonstrate the clinical utility of this battery of tests, the variance in normative values for these tests that exists across these studies suggests the need to develop reference values based on specific cancer diagnoses. Therefore, the purpose of this retrospective study was to develop reference ranges for these physical performance tests that are specific to subacute SCT recipients referred for physiotherapy. Such information will give clinicians valuable insight into the relative and absolute status of patients, a baseline from which treatment strategies can be designed, and a quantitative basis for assessing treatment effectiveness.
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Patients and methods
Patients
We reviewed the medical charts of 80 consecutive SCT recipients who had been referred to the Department of Rehabilitation Services (DRS) by physicians and physician extenders (advanced practice nurses and physician assistants) at UT MD Anderson Cancer Center between January 2006 and December 2007. These patients had undergone a single SCT as treatment for a hematological malignancy, and were not receiving glucocorticoids at the time of evaluation. After transplantation and hospital discharge, SCT recipients typically remain in close proximity to UT MD Anderson Cancer Center for the remainder of their 100 days post-transplant recovery period so that the engraftment can be monitored and medical complications, including neutropenic fever and GVHD can be managed. During this period SCT recipients receive daily or near daily outpatient services through the Ambulatory Treatment Center consisting of clinical monitoring and active and/or prophylactic treatment for infection, neutropenia, depression, GVHD, electrolyte imbalances and hematological deficits.
Patients in this study had been referred to DRS for evaluation and treatment by a physiotherapist, because they had significant physical/functional deficits and the potential to improve their functional capacity in response to physiotherapy. Referring staff used no fixed or consistent criteria for referring SCT recipients to DRS. Referred patients could refuse to participate in physiotherapy. Patients could also request a referral for physiotherapy services. This retrospective study was approved by the Institutional Review Board at UT MD Anderson Cancer Center.
Functional assessment
As a part of their initial physiotherapy evaluation, patients completed a battery of physical performance tests including a 6-min walk test (6-MWT), repeated sit-to-stand test and the 50-ft walk test. These tests have been demonstrated to be valid, reliable and correlated with the functional capacity of patients with cancer. 6 Tests were conducted by physiotherapists, who had been trained in the proper techniques for conducting these tests.
Each patient attempted a single 6-MWT, as described by the American Thoracic Society. 12 Briefly, patients were asked to walk around the perimeter of DRS gym (approximately 64 m in length) as quickly as possible for 6 min so as to cover as much distance as possible without running. Patients typically had indwelling i.v. lines that were attached to i.v. poles, which they pushed during this test. Elapsed time was provided to the patient at intervals of 1 min, and testers limited other verbal encouragement to 'you are doing well' or 'keep up the good work'. 7 The tester followed the patient during the test for safety reasons and pushed a surveyor's wheel to record distance covered by the patient. Results of this test are reported in meters. The repeated sit-to-stand test required the patient to rise from a standard armchair (height: 18 inches or 45.72 cm) to a standing position (knees fully extended) twice, as quickly as possible, without using his or her upper extremities. Elapsed time was recorded by a stopwatch and results reported in seconds. The test was repeated twice, and the results were averaged. For the 50-ft walk test, each subject was asked to walk as quickly as possible over a level and straight 50-ft course marked off on the DRS gym. Elapsed time was measured with a stopwatch and results reported in seconds.
Statistical analysis
All statistical calculations including measures of central tendency, t-tests, correlation coefficients and confidence intervals were carried out using SPSS statistical package version 16.0 for Windows (SPSS; Chicago, IL, USA). All data met the assumptions for parametric analysis. Means and s.ds. were calculated for each test. Confidence intervals at the 95% level were calculated for all means in our study and for those test results that were common in the Simmonds 6 study. Correlation coefficients examining direction and strength of linear relationship between performance and demographic variables were calculated using Pearson's product moment correlation coefficient (Pearson's r). Subgroup differences were analyzed by means of an unpaired t-test. Alpha was set a priori at 0.05.
Results
Patient demographics are presented in Table 1 . Patients averaged 53.5 years of age (range 21-68), males comprised the majority of patients (57.5%) and they were, on average, almost 5-years older than the female patients. This difference did not rise to significance. Based on body mass index, these patients were generally overweight (body mass index 25-29.9) with 1 patient classified as underweight (body mass indexo18.5) and 13 patients classified as obese (body mass index 430). 13 This cohort of patients had completed an average of 40 of their anticipated 100 day post-transplant stay (range: 13-136 days) when they were evaluated. Discharge home had been delayed for the patient who started rehabilitation 136 days post transplant because of post-transplant medical complications. Leukemia accounted for 57% of cancer diagnoses in this cohort of patients (Table 2) with AML the single most prevalent diagnosis (33.75%). PBSCs provided the largest source for transplanted cells (Table 3 ) and 51.2% of the patients received their donor cells from a matched unrelated donor.
Of the 80 patients in this study, 1 patient was unable to complete the entire battery of tests, 2 were unable to complete either walking test, 5 were unable to complete the 6-MWT and 4 were unable to complete the repeated sit-tostand test. Orthopedic problems and lower extremity edema prevented three patients from completing one or more performance tests, but patient complaints of fatigue were the predominant reason given for not completing a performance test. Outcomes (mean ± s.d. and 95% confidence intervals) for the physical performance tests are presented in Table 4 . Comparative analysis of age and gender subgroups did not show any significant differences between these subgroups for any single performance test. Confidence intervals for speed and distance tests for both this study and for the study of Simmonds 6 are presented in Figures 1-3 . No overlap in 95% confidence intervals were noted for any of the three physical performance measures. Physical performance testing was completed with no untoward events.
Results from several studies have demonstrated that several anthropomorphic measures significantly correlate with performance on physical performance tests, including age, height, weight and body mass index.
14-16 Therefore, we carried out a correlational analysis to determine if any anthropomorphic factors demonstrated a linear relationship with any of the performance measures. Results of these analyses are presented in Table 5 . Only age demonstrated a significant correlation with any performance measure, and that was with the results of 6-MWTs. Although only poor, this relationship was present in both male patients and female patients and was in the expected direction; distance ambulated declined as age increased. 14, 15 The patients in this study completed these physical performance tests at widely disparate time points in their Table 2 Cancer diagnosis of the patients involved in the current study Figure 1 A graphical representation of the means and 95% confidence intervals for the 6-min walk test (6-MWT) determined for sub-acute SCT recipients (current study) and a heterogeneous oncology patient population. 6 The vertical line identifies 326.3 m, the mean of the mean of our study and that of Simmonds. 6 A longer distance indicates a greater physical capacity.
sub-acute recovery period (range: 13-136 days), raising the possibility that spontaneous recovery may have occurred during this period. To test this possibility, individual outcomes for each of the three performance measures have been plotted against the elapsed time between transplantation and initial physiotherapy evaluation (Figure 4) , and the quality of the linear relationship between these variables examined (Pearson's r). These analyses indicate that a poor to low but significant correlation (rp0.282) existed between the 50-ft walk time and the time post transplant. No other significant correlations were observed.
Discussion
The principal contribution of this study is that it provides reference values for physical performance tests (50-ft walk, 6-MWT distance and repeated sit-to-stand) that are clinically useful in quantifying both the physical and functional capacity of sub-acute SCT recipients referred for physiotherapy services. Such values provide clinicians with needed standards with which to assess and compare intervals for the repeated sit-to-stand test time determined for sub-acute SCT recipients (current study) and a heterogeneous oncology patient population. 6 The vertical line identifies 6.15 s, the mean of the mean of our study and that of Simmonds. 6 A longer time indicates a slower physical performance.
Time (Seconds)
Group
Current study Simmonds (6) Figure 3 A graphical representation of the means and 95% confidence intervals for the 50-ft walk test time determined for sub-acute SCT recipients (current study) and a heterogeneous oncology patient population. 6 The vertical line identifies 15.12 s, the mean of the mean of our study and that of Simmonds. 6 A longer time indicates a slower physical performance. patient status, performance and progression. 3, 4, 11 It is important to note that these tests were carried out in a clinical setting, well received by clinicians and were safe as evidenced by the absence of any adverse event during testing. Of significance is the fact that these performance values reported for the SCT recipients differ substantially from those reported for a heterogeneous oncology population. 6 Specifically, the patients in this study were approximately twice as fast in completing the timed tests as a heterogeneous oncology population, and they could walk about 33% further during the 6-MWT. The clear separation in performance outcomes between the patients in this study and those reported by Simmonds (Figures 1-3) supports the suggestion that sub-acute SCT populations differ substantially from a heterogeneous oncology population in terms of their respective physical performance and functional capacity.
Other investigators have also found that reference values for physical performance tests derived from a heterogeneous oncology population differ substantially from those describing a patient population having a common cancer diagnosis.
7-10 Specifically, Basen-Engquist et al. 8 reported that breast cancer survivors were fitter than a heterogeneous oncology population, as did Montoya et al. 7 for advanced lung cancer patients. Given the complexities of various cancers and the wide variety of adverse effects arising from cancer treatments, differences in functional performance measures should be anticipated. However, such differences should not discourage the use of these validated functional performance measures given the many advantages they offer clinicians. 4, 6, 11, 17, 18 In the mean time, greater efforts should be made to establish reference values for these functional tests predicated on specific cancer diagnoses. 6, 18 The emerging picture of the functional capacity of SCT recipients is one of significant decline during and immediately after transplantation 2, 19, 20 followed by limited or no improvement of functional capacity during the sub-acute phase of recovery. [19] [20] [21] Results from this study provide further support of this clinical picture. For example, our patients completed the timed tests (50-ft walk, repeated sitto-stand) in less time and covered a greater distance in the 6-MWT than did the healthy control group included in the study by Simmonds.
6 These differences were consistent across age and gender. Patients in this study were able to walk approximately 75% of the 6-MWT distance reported from a meta analysis of 6-MWT distances for healthy individuals over the age of 60. 22 Furthermore, 6-MWT distances observed in the sub-acute SCT recipients approximate the distances covered by both pulmonary and cardiac patients, 23, 24 further suggesting a reduced functional capacity in these patients. An important secondary observation from this study is the fact that physical performance was similar regardless of how much time had transpired since transplantation (Figure 4 ). These findings support the suggestion by Courneya et al. 25 that patients in the sub-acute phase of recovery generally have a disinterest in voluntarily engaging in exercise activities.
Results from physical performance tests are often used as either a direct or indirect measure of patient functional capacity. For example, the ability to walk a given distance is an important index of one's quality of life and helps to define the ability of a patient to undertake or participate in day-to-day activities. [26] [27] [28] Similarly, repeated sit-to-stands are essential for performing activities of daily living, and the ability to walk fast is essential for completing such tasks as successfully walking across the street. Simmonds 6 has more formally described the relationship between physical performance capacity and functional capacity by demonstrating that patients' self reports of their functional capacity (Functional Status Index) is modestly correlated to the results of these performance measures. Ryan et al. 28 also found a weak but statistically significant relationship between patients' perception of their ability to perform daily activities and the results from physical performance tests. Functional capacity and physical capacity have also been shown to change in tandem in allo-SCT recipients immediately after transplantation. 5 Hence, it seems reasonable to suggest that the results from these physical performance tests reflect functional capacity and, more importantly, changes in test results can be used to document changes in the ability of patients to engage in activities associated with daily living. 6, 26, 28 A major complication of allo-SCT is acute GVHD, which is estimated to occur upwards in 41% of transplant recipients. 29 High-dose corticosteroid treatment remains the first line of defense for treating this adverse event. 30 Although very effective, these drugs are responsible for a plethora of adverse side effects, particularly a loss of muscle mass and strength. 30, 31 As such, the functional performance by SCT recipients on corticosteroids may be significantly compromised. For these reasons, only data from patients not on corticosteroids were included in the data analysis.
Limitations of this study must be acknowledged. First, this study suffers from the shortcomings inherent in a retrospective study design. Patients evaluated for the purposes of this study were referred to DRS by physicians and mid-level providers in the Ambulatory Treatment Center. As no fixed criteria existed for referring patients to DRS, referral criteria probably varied across this group of referring physicians and mid-level providers. Further, SCT recipients were given a referral to DRS for evaluation if they requested it, and patients could also refuse a referral. These conditions raise concerns about how broadly representative is this group of patients, and hence the data, are relative to the overall sub-acute SCT recipient population as a whole. The reference values presented in this study can be applied to those sub-acute SCT recipients deemed to be candidates for physiotherapy. Extending these values to a broader population of sub-acute SCT recipients should be undertaken cautiously until results from performance measured in a cross-section of these patients have been reported.
Conclusion
Despite some shortcomings, our findings are clinically relevant in that they provide reasonable estimates of reference values for these physical performance tests, which can be used by clinicians to gain insight into the physical and functional status of sub-acute SCT recipients.
